These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23833379)

  • 41. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P; Likanonsakul S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zidovudine + lamivudine: new preparation. Fewer tablets required.
    Prescrire Int; 1999 Apr; 8(40):39-40. PubMed ID: 10848057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antiretroviral-induced toxiderma in HIV-infected patients].
    Caumes E; Bossi P; Katlama C; Bricaire F
    Presse Med; 2003 Sep; 32(28):1325-33. PubMed ID: 14506444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
    Santos RP; Ramilo O; Barton T
    Pediatr Infect Dis J; 2007 Nov; 26(11):1053-6. PubMed ID: 17984815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.
    Quercia R; Perno CF; Koteff J; Moore K; McCoig C; St Clair M; Kuritzkes D
    J Acquir Immune Defic Syndr; 2018 Jun; 78(2):125-135. PubMed ID: 29474268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors.
    Morris AA; Baudouin SV; Snow MH
    AIDS; 2001 Jan; 15(1):140-1. PubMed ID: 11192863
    [No Abstract]   [Full Text] [Related]  

  • 48. Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis.
    Schiano TD; Lissoos TW; Ahmed A; Siano C; Zaitman D; Cohn G; Ehrenpreis ED
    Am J Gastroenterol; 1997 Sep; 92(9):1563-4. PubMed ID: 9317091
    [No Abstract]   [Full Text] [Related]  

  • 49. Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
    Rey D; Krebs M; Partisani M; Hess G; Cheneau C; Priester M; Bernard-Henry C; de Mautort E; Lang JM
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):530-4. PubMed ID: 17057610
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Severe anoxic hepatic necrosis in an HIV-1-hepatitis C virus-co-infected patient starting antiretroviral triple combination therapy.
    Karras A; Rabian C; Zylberberg H; Hermine O; Duchatelle V; Durand F; Valla D; Viard JP
    AIDS; 1998 May; 12(7):827-9. PubMed ID: 9619823
    [No Abstract]   [Full Text] [Related]  

  • 51. Lactic acidosis secondary to nucleoside analogue antiretroviral therapy.
    Khouri S; Cushing H
    AIDS Read; 2000 Oct; 10(10):602-6. PubMed ID: 11068807
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.
    Schweinsburg BC; Taylor MJ; Alhassoon OM; Gonzalez R; Brown GG; Ellis RJ; Letendre S; Videen JS; McCutchan JA; Patterson TL; Grant I;
    J Neurovirol; 2005 Aug; 11(4):356-64. PubMed ID: 16206458
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
    Wang LH; Chittick GE; McDowell JA
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GW420867X administered to HIV-1-infected patients alone and in combination with lamivudine and zidovudine.
    Arasteh K; Wood R; Müller M; Prince W; Cass L; Moore KH; Dallow N; Jones A; Klein A; Burt V; Kleim JP
    HIV Clin Trials; 2001; 2(4):307-16. PubMed ID: 11590533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
    Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
    AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Fatal lactic acidosis in a patient with acquired immunodeficiency syndrome treated with stavudine, lamivudine and indinavir].
    Tanaka K; Fukahori S; Jojima H; Fujimatsu Y; Shiraishi K; Tanaka M; Okubo Y; Honda J; Oizumi K
    Kansenshogaku Zasshi; 1999 Dec; 73(12):1232-5. PubMed ID: 10655686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
    Walker VE; Poirier MC
    Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
    [No Abstract]   [Full Text] [Related]  

  • 59. Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
    DeJesus E; McCarty D; Farthing CF; Shortino DD; Grinsztejn B; Thomas DA; Schrader SR; Castillo SA; Sension MG; Gough K; Madison SJ;
    Clin Infect Dis; 2004 Aug; 39(3):411-8. PubMed ID: 15307010
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Opiates withdrawal syndrome after treatment with zidovudine + lamivudine + abcavir in patients with positivity for HIV and treated with methadone].
    Pardo López MA; Cuadrado Pastor JM; Pérez Hervás MP; Fernández Villalba E
    Rev Clin Esp; 2003 Aug; 203(8):407-8. PubMed ID: 12855129
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.